Nanobiotix S.A. (NANO.PA) • EURONEXT
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold NANO.PA in your mock portfolio yet.
Nanobiotix S.A. is currently loss‑making, as indicated by its negative EPS and PE ratio. The lack of profitability suggests that the investment thesis is driven more by future growth expectations and pipeline potential than by current financial strength. Until there is a clear path to positive earnings, the financial profile remains high risk.
The stock’s recent price action is strongly positive, with a 58.2% gain over the last month and a price well above its 200‑day moving average. This suggests strong upward momentum and a favorable technical backdrop, albeit with elevated volatility and potential for pullbacks. The move appears momentum‑driven rather than supported by earnings.
Alternative data for Nanobiotix S.A. shows modest and relatively slow growth in digital presence and hiring, with small follower bases and low web traffic. These signals do not point to a strong commercial ramp or broadening retail/investor awareness yet. Overall, they neither strongly confirm nor contradict the bullish technical picture.
Nanobiotix S.A. presents a classic high‑risk, high‑reward biotech profile: technically strong and momentum‑driven, but underpinned by weak current financials and modest alternative data signals. The recent price surge and position well above the 200‑day moving average are bullish from a trading standpoint, yet the negative earnings and limited evidence of scaling operations temper the outlook. Overall, the setup appears neutral, skewed toward speculative rather than fundamentally grounded upside.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started